Coordinatore | UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
Nazionalità Coordinatore | Switzerland [CH] |
Totale costo | 7˙821˙538 € |
EC contributo | 5˙999˙436 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2009-single-stage |
Funding Scheme | CP-FP |
Anno di inizio | 2010 |
Periodo (anno-mese-giorno) | 2010-01-01 - 2014-12-31 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | coordinator | 684˙400.00 |
2 |
UNIVERSITEIT ANTWERPEN
Organization address
address: PRINSSTRAAT 13 contact info |
BE (ANTWERPEN) | participant | 1˙017˙911.00 |
3 |
THE FOUNDATION FOR MEDICAL RESEARCHINFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV
Organization address
address: WEIZMANN STREET 6 contact info |
IL (Tel Aviv) | participant | 922˙947.00 |
4 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 806˙190.00 |
5 |
UNIVERSITA CATTOLICA DEL SACRO CUORE
Organization address
address: Largo Agostino Gemelli 1 contact info |
IT (MILANO) | participant | 592˙349.60 |
6 |
ARTTIC
Organization address
address: Rue du Dessous des Berges 58A contact info |
FR (PARIS) | participant | 374˙041.30 |
7 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 373˙549.00 |
8 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: CALLE ROSSELLO 149 PUERTA BJS contact info |
ES (BARCELONA) | participant | 267˙567.80 |
9 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 235˙389.74 |
10 |
JULIUS-MAXIMILIANS UNIVERSITAET WUERZBURG
Organization address
address: SANDERRING 2 contact info |
DE (WUERZBURG) | participant | 212˙987.00 |
11 |
UNIVERSYTET MEDYCZNY W LODZI.
Organization address
address: Al. Kosciuszki, 4 contact info |
PL (LODZ) | participant | 178˙761.80 |
12 |
INSTITUTE FOR INFECTIOUS DISEASES PROF DR. MATEI BALS
Organization address
address: Street Dr. C. Grozovici 1 1 contact info |
RO (Bucharest) | participant | 145˙975.00 |
13 |
Clinical Center of Serbia
Organization address
address: Pasterova 2 contact info |
RS (Belgrade) | participant | 145˙103.30 |
14 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 34˙811.60 |
15 |
Fondation hopital Saint Joseph
Organization address
address: Rue Raymond Losserand 185 contact info |
FR (Paris) | participant | 7˙451.86 |
16 |
STICHTING NIJMEEGS INTERCONFESSIONEEL ZIEKENHUIS CANISIUS WILHELMINA
Organization address
address: WEG DOOR JONKERBOS 100 contact info |
NL (NIJMEGEN) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Many results drawn from previous studies of the effect of antibiotic use on emergence, selection and spread of antimicrobial resistance (AMR) have lacked a holistic view combining all aspects into one study. The SATURN project aims to study the impact of antibiotic exposure on AMR with a multidisciplinary approach that bridges molecular, epidemiological, clinical and pharmacological research. Two types of clinical studies will be conducted: First, a randomized trial will be performed to resolve an issue of high controversy (antibiotic cycling vs. mixing). Second, 3 observational studies will be conducted to rigorously study issues surrounding the effect of antibiotic use on AMR that are not easily assessable through randomized trials. These clinical studies will serve as a platform to 2 complementary workpackages (microbiology & pharmacology) that will perform important investigations relevant to this call. The work package focusing on molecular studies will generate new evidence about the changes effected by antibiotic therapy on commensal organisms or opportunistic pathogens in the oropharyngeal, nasal and gastro-intestinal flora and study AMR mechanisms and the dissemination of successful clones of fluoroquinolone-resistant, carbapenem-resistant or extended-spectrum beta-lactamase harboring Gram-negative bacteria, MRSA and fluoroquinolone-resistant viridans streptococci. The purpose of the pharmacodynamic study is to model the relationships between antibiotic exposure and AMR emergence over time for various classes of agents. In summary, the overarching rationale of SATURN is to improve methodological standards and conduct research that will help to better understand the impact of antibiotic use on acquisition, selection and transmission of AMR in different environments, by combining analyses of molecular, individual patient-level and ecologic data. The anticipated results may guide clinical and policy decisions to ultimately reduce the burden of AMR in Europe.'
Antibiotic misuse triggers the emergence of drug-resistant bacteria. Understanding the mechanisms underlying this phenomenon should help develop appropriate measures.